@castltrastondrs.medsky.network#Medsky🧪 #IDsky #pharmsky #publichealth #vaccinesmater #LongCOVID is an ongoing health condition that may occur after being infected with the #SARSCoV2 virus.🦠 can still be detected in the bodies of some people with LC.
🧪A clinical trial for LC found that treating patients
@josemolinagb.bsky.socialBad news for patients with MDR infections…
Merck has announced that imipenem/relebactam supply will be discontinued in US by the end of September.
Guess this will extend to Europe soon?
We definitely need new payment models for antibiotics 🙁
@citc-tb.bsky.socialRegistration is open for the 2027 End TB Conference!
📅 February 24-27, 2027
📍Vancouver, BC, Canada
#EndTB #TBSky #IDSky #Tuberculosis
@theunion.org
@guerreroespejo.bsky.social
@aliciaault.bsky.socialYet another study supporting the life-saving potential of vaccines.
@ichejournal.bsky.socialNew in ICHE:
Pilot study shows point‑of‑care molecular testing in nursing homes is feasible and supports stronger surveillance for RSV, influenza, and SARS-CoV-2.
@ichejournal.bsky.socialNew in ICHE: The changing epidemiology of outbreaks due to Ralstonia spp.: contamination of commercially manufactured injectables and solutions
@profandrewmac.bsky.socialGroundbreaking study from Alex Loukas and Paul Brindley reporting the generation and propagation of the first heritable
transgenic #schistosome line! 🧪 🪱 #IDSky
www.nature.com/articles/s41...
@contagionlive.bsky.socialIn the phase 3 study, the investigational monoclonal antibody, VYD2311, had fewer adverse events than an mRNA #COVID19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the 2 were given together. @invivyd.bsky.social #IDsky #Medsky
www.contagionlive.com/view/vyd2311...
@infectiobxl.bsky.socialOur comment published this month in @lancetmicrobe.bsky.social
Differential success of human papillomavirus vaccination in people living with HIV and solid organ transplant recipients: lessons for vaccine design in immunocompromised individuals.
#IDSky #HPV
@contagionlive.bsky.socialThe monoclonal antibody, Brelovitug, met the combined virologic and ALT response end point at week 24 in AZURE-1, with 56% response on 300 mg weekly and 45% on 900 mg every four weeks. #hepatitis #IDsky
www.contagionlive.com/view/monoclo...
@tomk.eurosky.social💊Manikomycin, the new antibiokid on the block!🧫
#MicrobioSky #IDSky #MedSky #AMR #AntimicrobialResistance
@lancetmicrobe.bsky.socialNew research article
Data-driven diagnostic reform in Ethiopia's transition to pLDH-based #malaria rapid diagnostic tests amid rising pfhrp2/3 deletions: a multisite, facility-based, cross-sectional study
@leprauk.bsky.socialEvery person affected by leprosy & lymphatic filariasis has a story that deserves to be heard. A story of resilience, a story of hope. We are proud to always focus on the person and not just the disease, which is why we want to tell their stories.
@q-linea.bsky.social
@guerreroespejo.bsky.social🧠 Clinical case
A 25-year-old man with HIV on ART (CD4: 218/mm³) presents with headache and diplopia.
Examination shows an isolated right VI nerve palsy.
He also has low-back pain and constipation.
👁️ What is your differential diagnosis?
@leprauk.bsky.socialLook beyond the headlines. What do the latest WHO leprosy figures mean? Maria del Mar Marais, Head of Programme Management Lepra UK, breaks down what the 2025 data really tells us at the midpoint of the WHO Global Leprosy Strategy 2021–2030: https://ow.ly/T1Jr50ZS7Ri